Scientific Knowledge Exchange on immunotherapy in lung cancer
In this Scientific Knowledge Exchange Prof. Dr. Solange Peters, Central University Hospital (CHUV) in Lausanne, and OA Dr. Georg Pall, Special Hospital in Wangen, discuss about immunotherapy in lung cancer.
Source: ASCO 2018
The following abstracts are discussed in this SKE:
Jotte RM et al, IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.
https://meetinglibrary.asco.org/record/165951/abstract
Lopes G et al: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.
https://meetinglibrary.asco.org/record/165950/abstract
Paz-Ares LG et al: Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).
https://meetinglibrary.asco.org/record/161684/abstract
Borghaei H et al: Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227.
https://meetinglibrary.asco.org/record/160783/abstract
Socinski MA et al: Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.